GO:2000691 negative regulation of cardiac muscle cell myoblast differentiation: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000691 describes any process that stops, prevents, or reduces the frequency, rate, or extent of cardiac muscle cell myoblast differentiation [QuickGO].
• This term is a biological_process node that sits at the intersection of cardiac development and muscle regeneration research.
• Key regulatory proteins include NET39, APOBEC2, CARP/CSRP3, and MyoD1, which modulate myoblast differentiation in skeletal and cardiac contexts.
• MicroRNAs and long non-coding RNAs such as MAAT act as negative regulators of myogenic differentiation.
• Dysregulation of this process is linked to neuromuscular disorders, muscle atrophy, and impaired cardiac regeneration.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of candidate regulators.
Description
GO:2000691, negative regulation of cardiac muscle cell myoblast differentiation, is a Gene Ontology biological_process term that captures the cellular programs which restrain cardiac myoblast differentiation [QuickGO]. Cardiac muscle cell myoblasts are precursor cells committed to the cardiomyocyte lineage; their differentiation must be tightly controlled to ensure proper heart development and to prevent premature or excessive differentiation that could deplete progenitor pools. Understanding the negative regulation of this process is critical for developmental biologists, regenerative medicine researchers, and drug discovery scientists aiming to modulate cardiac repair.
negative regulation of cardiac muscle cell myoblast differentiation At A Glance
| GO ID | GO:2000691 |
|---|---|
| GO term | negative regulation of cardiac muscle cell myoblast differentiation |
| Ontology | biological_process |
| Synonym | negative regulation of cardiac myoblast differentiation; negative regulation of myocardial precursor cell differentiation |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of cardiac muscle cell myoblast differentiation. |
| Major function | Restraining the differentiation of cardiac myoblast precursors to maintain progenitor pools and proper heart development. |
| Related processes | Muscle satellite cell dysfunction, myoblast differentiation, TGF-beta/Smad3 signaling, lncRNA-mediated regulation. |
| Key regulators | NET39, APOBEC2, CARP/CSRP3, MyoD1, microRNAs, lncRNA MAAT. |
| Disease relevance | Neuromuscular disorders, muscle atrophy, impaired cardiac regeneration. |
What Is GO:2000691?
In plain terms, GO:2000691 refers to any biological process that stops, prevents, or reduces the frequency, rate, or extent of cardiac muscle cell myoblast differentiation [QuickGO]. This includes molecular brakes such as transcriptional repressors, signaling pathways that antagonize differentiation cues, and non-coding RNAs that dampen pro-differentiation gene expression.
Why Is negative regulation of cardiac muscle cell myoblast differentiation Important in Cell Biology?
The negative regulation of cardiac muscle cell myoblast differentiation is essential for balancing cardiac progenitor pool maintenance and timely differentiation during heart development and repair. Disruption of this balance can lead to congenital heart defects, impaired regenerative capacity after injury, and muscle-wasting conditions. Therefore, identifying the molecular brakes of cardiac myoblast differentiation is a major goal for regenerative medicine and for understanding neuromuscular pathologies.
• Maintains cardiac progenitor cell pools by preventing premature differentiation.
• Coordinates heart development and maturation.
• Influences skeletal muscle regeneration through shared myogenic regulators.
• Dysregulation contributes to neuromuscular disorders and satellite cell-opathies.
• Modulates muscle atrophy pathways via lncRNAs such as MAAT.
• Provides targets for CRISPR-based screens to identify novel regulators.
• Relevant to cardiac regeneration strategies after myocardial injury.
• Links microRNA networks to cardiac and skeletal muscle development.
• Involves TGF-beta/Smad3 signaling as a negative feedback mechanism.
• Offers biomarkers and therapeutic entry points for muscle diseases.
What Happens During negative regulation of cardiac muscle cell myoblast differentiation?
Initiation of differentiation blockade
In simple terms: The cell receives signals that tell it to stop becoming a heart muscle cell.
Negative regulation begins when extracellular or intracellular cues activate repressive pathways. For example, TGF-beta/Smad3 signaling can inhibit differentiation of muscle satellite cells, a process relevant to cardiac myoblast regulation. Similarly, the lncRNA MAAT acts as a negative regulator of muscle atrophy and can influence differentiation programs.
Transcriptional repression of pro-differentiation genes
In simple terms: Master switches for muscle differentiation are turned off.
Transcriptional repressors such as NET39 and APOBEC2 negatively regulate myoblast differentiation by modulating the activity of key transcription factors like MyoD1. CARP (CSRP3) is a positive regulator of myogenesis, and its knockdown promotes TGF-beta/Smad3 signaling, indirectly affecting differentiation.
Non-coding RNA-mediated fine-tuning
In simple terms: Small RNA molecules act as brakes on differentiation.
MicroRNAs are critical regulators of skeletal and cardiac muscle development, often functioning as negative regulators of differentiation. The lncRNA MAAT controls multiple types of muscle atrophy through cis- and trans-regulatory actions, highlighting the role of non-coding RNAs in this process.
Protein stability and nuclear envelope control
In simple terms: Proteins that support differentiation are degraded or sequestered.
The nuclear envelope protein NET39 regulates myoblast differentiation, and its loss can alter the balance between proliferation and differentiation. APOBEC2 negatively regulates myoblast differentiation during muscle regeneration, suggesting that it promotes a undifferentiated state.
Integration with metabolic and signaling states
In simple terms: The cell's metabolic status influences the decision to differentiate.
Cardiolipin metabolism regulates the expression of MyoD1 and muscle development, linking mitochondrial function to the control of differentiation. This integration ensures that differentiation occurs only when metabolic conditions are favorable.
Key Genes Involved in GO:2000691 negative regulation of cardiac muscle cell myoblast differentiation
The following genes and proteins have been experimentally implicated in the negative regulation of cardiac muscle cell myoblast differentiation or closely related myogenic processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NET39 | Nuclear envelope protein that regulates myoblast differentiation | Loss-of-function studies show altered differentiation balance |
| APOBEC2 | Negative regulator of myoblast differentiation during muscle regeneration | Knockdown promotes differentiation; potential target for regeneration |
| CARP/CSRP3 | Positive regulator of myogenesis; its knockdown enhances TGF-beta/Smad3 signaling | Modulates differentiation via TGF-beta pathway |
| MyoD1 | Master transcription factor for muscle differentiation; regulated by cardiolipin metabolism | Central node for differentiation control |
| MAAT (lncRNA) | Long non-coding RNA that controls muscle atrophy via cis- and trans-regulation | Inhibition controls multiple types of muscle atrophy |
| miRNAs (e.g., miR-1, miR-133) | MicroRNAs that modulate skeletal and cardiac muscle development | Fine-tune differentiation timing |
| TGF-beta/Smad3 | Signaling pathway that inhibits differentiation | Key negative regulator in satellite cells |
| Myostatin | Negative regulator of muscle growth; downregulates CARP | Therapeutic target for muscle wasting |
| CSRP3 | Cysteine-rich protein 3, involved in myogenesis | Knockdown inhibits chicken satellite cell differentiation |
| NET39 (Nesprin-1) | Links nuclear envelope to cytoskeleton | Mutations linked to neuromuscular disorders |
| APOBEC2 | DNA/RNA editing enzyme family member | Negative regulator in muscle regeneration |
| MyoD1 | Basic helix-loop-helix transcription factor | Regulated by cardiolipin metabolism |
| MAAT | lncRNA involved in muscle atrophy | Potential therapeutic target |
| miR-1 | Muscle-specific microRNA | Regulates cardiac and skeletal muscle development |
| miR-133 | Muscle-specific microRNA | Modulates myoblast proliferation and differentiation |
| TGF-beta | Cytokine that inhibits myogenesis | Signaling axis in differentiation blockade |
| Smad3 | Intracellular mediator of TGF-beta signaling | Promotes differentiation inhibition |
| Myostatin | Member of TGF-beta superfamily | Downregulates CARP in CFM cells |
How Is negative regulation of cardiac muscle cell myoblast differentiation Regulated?
The negative regulation of cardiac muscle cell myoblast differentiation is controlled by a network of signaling pathways, transcription factors, and non-coding RNAs. TGF-beta/Smad3 signaling acts as a potent inhibitor of differentiation in muscle satellite cells. The lncRNA MAAT modulates muscle atrophy through cis- and trans-regulatory mechanisms, impacting differentiation programs. MicroRNAs such as miR-1 and miR-133 fine-tune the timing of differentiation by targeting pro-differentiation transcripts. Additionally, metabolic cues like cardiolipin metabolism influence MyoD1 expression, integrating mitochondrial status with differentiation control.
negative regulation of cardiac muscle cell myoblast differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NET39 | Neuromuscular disorders, satellite cell-opathies | Knockout mouse, patient-derived iPSCs |
| APOBEC2 | Muscle regeneration defects | Overexpression and knockout in C2C12 cells |
| CSRP3 | Muscle atrophy, myopathy | Knockdown in chicken satellite cells |
| MAAT | Muscle atrophy | lncRNA inhibition in mouse models |
| MyoD1 | Cardiac and skeletal muscle development | Cardiolipin metabolism mutants |
Neuromuscular disorders and satellite cell-opathies
Dysfunction of muscle satellite cells, which share regulatory mechanisms with cardiac myoblasts, contributes to neuromuscular disorders. Mutations in nuclear envelope proteins like NET39 are linked to satellite cell-opathies, highlighting the importance of negative regulation in disease.
Muscle atrophy
The lncRNA MAAT controls multiple types of muscle atrophy by regulating gene expression in cis and trans. Inhibition of MAAT can ameliorate atrophy, suggesting that negative regulation of differentiation is intertwined with atrophy pathways.
Cardiac regeneration failure
After myocardial injury, the heart's limited regenerative capacity is partly due to insufficient cardiomyocyte differentiation. Understanding the brakes on cardiac myoblast differentiation could inform strategies to enhance regeneration.
From negative regulation of cardiac muscle cell myoblast differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate cardiac myoblast differentiation? | CRISPR knockout in iPSC-derived cardiomyocytes |
| Does a point mutation in gene X alter its repressive function? | CRISPR point-mutation knock-in in C2C12 cells |
| Does overexpression of gene X block differentiation? | Lentiviral overexpression in primary myoblasts |
| Does a tagged version of gene X interact with MyoD1? | Knock-in of FLAG/HA tag at endogenous locus |
| Which lncRNAs regulate cardiac myoblast differentiation? | CRISPR library screening with lncRNA guides |
| Does gene X affect TGF-beta/Smad3 signaling? | Smad3 reporter assays in knockout cells |
How to Study the negative regulation of cardiac muscle cell myoblast differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify pathways altered by gene knockout |
| Proteomics | Protein abundance and interactions | Map repressor complexes |
| Immunofluorescence | Differentiation marker expression | Quantify myotube formation |
| CRISPR knockout screen | Loss-of-function phenotypes | Discover novel negative regulators |
| CRISPR activation screen | Gain-of-function phenotypes | Identify brakes on differentiation |
| ChIP-seq | Transcription factor binding sites | Map MyoD1 occupancy |
| Ribo-seq | Translational efficiency | Assess differentiation-specific translation |
Transcriptomic profiling (RNA-seq)
RNA sequencing can identify global changes in gene expression upon knockout or overexpression of candidate negative regulators, revealing pathways such as TGF-beta/Smad3.
Proteomics and interactomics
Mass spectrometry-based proteomics can uncover protein-protein interactions involving NET39, APOBEC2, and MyoD1, elucidating how they repress differentiation.
Imaging of differentiation markers
Immunofluorescence for myosin heavy chain and cardiac troponin T allows quantification of differentiation efficiency in vitro.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of cardiac myoblast differentiation, as demonstrated in related muscle studies.
How CRISPR Can Be Used to Study GO:2000691 negative regulation of cardiac muscle cell myoblast differentiation
Knockout
CRISPR knockout of candidate negative regulators such as NET39 or APOBEC2 can test whether their loss accelerates cardiac myoblast differentiation, providing causal evidence.
Point Mutation
Introducing point mutations in genes like CSRP3 or MyoD1 can dissect domain-specific functions in differentiation repression, as shown in related muscle studies.
Knock-in
Knock-in of epitope tags or reporter genes at endogenous loci enables real-time tracking of protein expression and localization during differentiation.
Overexpression
Overexpression of suspected negative regulators like APOBEC2 or lncRNA MAAT can confirm their ability to block differentiation in cardiac myoblast models.
How EDITGENE Supports negative regulation of cardiac muscle cell myoblast differentiation Research
Researchers studying negative regulation of cardiac muscle cell myoblast differentiation-related genes often need to determine whether a candidate gene is causally involved in the differentiation blockade. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac muscle cell myoblast differentiation research.
Frequently Asked Questions About negative regulation of cardiac muscle cell myoblast differentiation
What is GO:2000691?
GO:2000691 is a Gene Ontology biological_process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cardiac muscle cell myoblast differentiation [QuickGO].
What genes are involved in negative regulation of cardiac muscle cell myoblast differentiation?
Key genes include NET39, APOBEC2, CARP/CSRP3, MyoD1, and non-coding RNAs such as MAAT and microRNAs.
How is cardiac myoblast differentiation negatively regulated?
Through transcriptional repressors, signaling pathways like TGF-beta/Smad3, and non-coding RNAs that dampen pro-differentiation gene expression.
What diseases are associated with dysregulation of this process?
Neuromuscular disorders, muscle atrophy, and impaired cardiac regeneration have been linked to altered negative regulation.
What experimental models are used to study GO:2000691?
CRISPR knockout, point mutation, knock-in, and overexpression in cell lines such as C2C12 and iPSC-derived cardiomyocytes.
Which microRNAs regulate cardiac muscle development?
miR-1 and miR-133 are well-known regulators of skeletal and cardiac muscle development.
What is the role of lncRNA MAAT in muscle atrophy?
MAAT controls multiple types of muscle atrophy through cis- and trans-regulatory actions, and its inhibition can ameliorate atrophy.
How does TGF-beta signaling inhibit myoblast differentiation?
TGF-beta activates Smad3, which represses pro-differentiation genes, as shown in chicken satellite cells.
Can CRISPR screens identify new regulators of cardiac myoblast differentiation?
Yes, genome-wide CRISPR screens have been used to discover novel modulators of muscle differentiation.
What is the difference between positive and negative regulation of myoblast differentiation?
Positive regulation promotes differentiation, while negative regulation restrains it; both are essential for proper muscle development.
Conclusion
GO:2000691, negative regulation of cardiac muscle cell myoblast differentiation, is a critical biological process that ensures proper cardiac development and muscle homeostasis. Dysregulation of this process contributes to neuromuscular disorders and muscle atrophy, making it a compelling area for therapeutic intervention. Leveraging CRISPR-based models and multi-omics approaches will accelerate the discovery of novel regulators and drug targets.
References
- 1. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 2. Liu GH et al.. 2009. Regulation of myoblast differentiation by the nuclear envelope protein NET39.. Mol Cell Biol 29(21):5800-12 PMID: 19704009
- 3. Ohtsubo H et al.. 2017. APOBEC2 negatively regulates myoblast differentiation in muscle regeneration.. Int J Biochem Cell Biol 85:91-101 PMID: 28215905
- 4. Vo L et al.. 2023. Cardiolipin metabolism regulates expression of muscle transcription factor MyoD1 and muscle development.. J Biol Chem 299(3):102978 PMID: 36739949
- 5. Callis TE et al.. 2007. MicroRNAs in skeletal and cardiac muscle development.. DNA Cell Biol 26(4):219-25 PMID: 17465888
- 6. Ma G et al.. 2014. CARP, a myostatin-downregulated gene in CFM Cells, is a novel essential positive regulator of myogenesis.. Int J Biol Sci 10(3):309-20 PMID: 24644428
- 7. Han S et al.. 2019. Knockdown of CSRP3 inhibits differentiation of chicken satellite cells by promoting TGF-β/Smad3 signaling.. Gene 707:36-43 PMID: 30930226
- 8. Li J et al.. 2021. Inhibition of lncRNA MAAT Controls Multiple Types of Muscle Atrophy by cis- and trans-Regulatory Actions.. Mol Ther 29(3):1102-1119 PMID: 33279721
